Nuvilex Contracts With University of Veterinary Medicine in Vienna to Conduct Preclinical Studies on the Use of Cell-in-a Box(R) to Develop Diabetes Treatment

SILVER SPRING, Md., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the University to perform "in vitro" and animal studies that use the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has been granted worldwide, royalty-free, rights to use the results of the research conducted by the University for all commercial purposes.

Nuvilex Secures Worldwide License for Insulin-Producing Cells From University of Technology, Sydney, for Use in Developing Diabetes Treatment

SILVER SPRING, Md., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants Nuvilex the worldwide rights to use human insulin-producing cells, termed "Melligen" cells, developed by Prof. Ann Simpson and her colleagues at UTS for the development of a treatment for insulin-dependent (Type 1 or juvenile-onset) diabetes. Type 1 diabetics are unable to produce the insulin required to transport glucose (blood sugar) from the blood to the inside of cells where it is used as a source of energy. The beta islet cells of the pancreas (Islets of Langerhans) of Type 1 diabetics that normally produce insulin have been destroyed by an autoimmune disease.

Nuvilex Applies to FDA for Orphan Drug Designation for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer

SILVER SPRING, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. If granted, Orphan Drug Designation in the United States will provide Nuvilex special development and commercial assistance from the FDA, including a 7 year period of marketing exclusivity. This latest submission of Nuvilex's pancreatic cancer treatment for the Orphan Drug Designation follows the application Nuvilex recently made to the European Medicines Agency (EMA) in September, 2014.

Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board

SILVER SPRING, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of Nuvilex's newly formed Scientific Advisory Board.

Nuvilex Announces Strategic Changes to Leadership Team and Appoints Prof. Dr. Walter H. Gunzburg as Chief Scientific Officer

SILVER SPRING, Md., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of Nuvilex, has been appointed Chairman of the Board of Directors and that Prof. Dr. Walter H. Gunzburg has been appointed to the post of Chief Scientific Officer. In addition, as part of the Company's on-going transition to becoming a fully integrated biotechnology company, Chairman and Chief Financial Officer, Patricia Gruden, Directors Timothy Matula and Robert Bowker and Chief Scientific Officer Dr. Robert F. Ryan have resigned from their respective positions.

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use of Cell-in-a-Box(R) for Treatment of Diabetes

SILVER SPRING, Md., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, published a scientific review in the journal Diabetes Research and Treatment: Open Access. The article addressed the use of cell encapsulation in developing a treatment for type 1 (insulin-dependent or juvenile-onset) diabetes and discussed advantages of using the Cell-in-Box(R) live cell sulfate-based encapsulation technology over other forms of cell encapsulation.

Nuvilex Updates Shareholders on Recent Activities and Discusses Future Plans for Development of Treatments for Cancer and Diabetes

SILVER SPRING, MD, September 18, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today provides its shareholders with an update on recent activities of Nuvilex and outlines future plans for the development of treatments in the areas of cancer and diabetes. This press release is the version that was to have been published earlier this morning.  

Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer

SILVER SPRING, Md., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. Nuvilex's pancreatic cancer treatment consists of the combination of Cell-in-a-Box(R) with low doses of the anticancer drug ifosfamide. The Cell-in-a-Box(R) portion of the treatment consists of live cells capable of converting ifosfamide into its cancer-killing form that have been enclosed in protective pin-head sized spherical capsules that are composed of bio-inert cellulose.

Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid

SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.

Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer

SILVER SPRING, Md., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer has been published in the scientific journal Pharmaceutics. The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer." The entire report can be viewed by clicking http://www.mdpi.com/1999-4923/6/3/447 and then clicking on "Full-Text PDF" on the left side of the page.